Form 4: Ginkgo Bioworks Executive Steven P. Coen Reports Stock Transactions

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., reports the vesting and sale of Class A Common Stock to cover tax obligations.

Summary

• On July 1, 2024, Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., acquired 23,496 shares of Class A Common Stock through the vesting of Restricted Stock Units (RSUs).
• An additional 6,250 shares were acquired on the same day through the vesting of more RSUs.
• On July 2, 2024, Coen sold 13,520 shares of Class A Common Stock at a price of $0.326 per share.
• These sales were to cover tax withholding obligations related to the vesting of the RSUs and do not represent discretionary trades.
• Following these transactions, Coen directly owns 195,058 shares of Class A Common Stock.
• Coen also holds 798,873 RSUs and 275,001 RSUs.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are made by executives at companies like Amyris and Zymergen (now Ginkgo Bioworks), reflecting stock transactions related to compensation and tax obligations.
• The sale of shares to cover tax obligations is a common practice among executives receiving equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.

Key Dates